SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
GSK plc (GSK) trades at a trailing P/E of 15.0, forward P/E of 12.3. Trailing earnings yield is 6.67%, forward earnings yield 8.12%. PEG 0.13 (Peter Lynch undervalued ≤1.0). Graham Number is $11.30.
Criteria proven by this page:
- VALUE (49/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 12.3 (down from trailing 15.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.13 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 6.67% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 8.12% as earnings recover.
- Analyst consensus target $53.00 (-10.4% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 64/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
49/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GSK
Valuation Multiples
P/E (TTM)15.0
Forward P/E12.3
PEG Ratio0.13
Forward PEG0.16
P/B Ratio5.23
P/S Ratio2.61
EV/EBITDA8.4
Per Share Data
EPS (TTM)$1.42
Forward EPS (Est.)$4.80
Book Value / Share$3.99
Revenue / Share$8.13
FCF / Share$1.25
Yields & Fair Value
Earnings Yield6.67%
Forward Earnings Yield8.12%
Dividend Yield2.89%
Graham Number$11.30
SharesGrow IV$145.21 (+145.4%)
Analyst Target$53.00 (-10.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
66.5 |
-0.75 |
53.95 |
2.17 |
8.00% |
| 2017 |
34.9 |
0.56 |
-785.65 |
1.77 |
7.31% |
| 2018 |
16.3 |
0.12 |
13.50 |
1.91 |
6.67% |
| 2019 |
15.1 |
0.56 |
4.64 |
2.08 |
5.64% |
| 2020 |
9.3 |
0.40 |
2.69 |
2.20 |
7.42% |
| 2021 |
11.9 |
-2.45 |
2.56 |
2.11 |
7.67% |
| 2022 |
3.9 |
-0.36 |
5.52 |
1.99 |
7.30% |
| 2023 |
12.1 |
0.00 |
3.51 |
1.97 |
4.67% |
| 2024 |
21.4 |
-0.44 |
4.03 |
1.76 |
4.44% |
| 2025 |
13.2 |
0.11 |
4.51 |
2.31 |
3.40% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.46 |
$27.89B |
$912M |
3.3% |
| 2017 |
$0.78 |
$30.19B |
$1.53B |
5.1% |
| 2018 |
$1.82 |
$30.82B |
$3.62B |
11.8% |
| 2019 |
$2.32 |
$33.75B |
$4.65B |
13.8% |
| 2020 |
$2.86 |
$34.1B |
$5.75B |
16.9% |
| 2021 |
$2.70 |
$34.11B |
$4.39B |
12.9% |
| 2022 |
$2.40 |
$29.32B |
$4.92B |
16.8% |
| 2023 |
$2.40 |
$30.33B |
$4.93B |
16.2% |
| 2024 |
$1.24 |
$31.38B |
$2.58B |
8.2% |
| 2025 |
$2.72 |
$31.95B |
$5.59B |
17.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$4.81 |
$4.72 – $5.03 |
$45.62B |
$45.54B – $45.69B |
7 |
| 2027 |
$5.31 |
$5.09 – $5.78 |
$47.86B |
$45.45B – $48.98B |
7 |
| 2028 |
$5.56 |
$4.99 – $6.82 |
$49.08B |
$47.87B – $50.39B |
7 |
| 2029 |
$5.97 |
$5.77 – $6.17 |
$50.68B |
$49.42B – $52.02B |
2 |
| 2030 |
$5.90 |
$5.71 – $6.11 |
$50.1B |
$48.86B – $51.43B |
5 |
